EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, MAY 7, 2019
Media advisory: To contact corresponding author Hermann Brenner, M.D., M.P.H., email firstname.lastname@example.org. The full study is linked to this news release and a visual abstract is below.
Embed this link to provide your readers free access to the full-text article: This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/2732573?guestAccessKey=4603433e-571d-4e10-9155-6e0c558fbecc&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=050719
Bottom Line: Some observational studies have suggested that taking aspirin before undergoing colorectal cancer screening with a fecal immunochemical test for blood in stool might improve the ability of the test to detect cancer precursors. This randomized clinical trial included about 1,200 adults (between the ages of 40 and 80) who took a single dose of aspirin (300 mg) two days before collecting a stool sample for a fecal immunochemical test and about 1,200 adults who took a placebo. Researchers report a higher detection rate in the aspirin group but the difference between the two groups wasn’t statistically significant. A limitation of the study is that the results were based on relatively few individuals who had cancer precursors.
Authors: Hermann Brenner, M.D., M.P.H., German Cancer Research Center, Heidelberg, Germany, and coauthors
Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email email@example.com.